Nominations for the 2014 award are closed.
The AACR-Minorities in Cancer Research Jane Cooke Wright Lectureship was first presented in 2006. The lectureship is intended to give recognition to an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of minority investigators in cancer research.
The recipient of the award will receive an honorarium of $5,000, give a 50-minute lecture during the AACR Annual Meeting 2014 in San Diego, Calif. (April 5-9, 2014), and will be provided support for the winner and a guest to attend the AACR Annual Meeting 2014.
Learn more about Dr. Jane Cooke Wright.
- Candidacy is open to all cancer researchers who are affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science anywhere in the world. Such institutions include those in academia, industry or government.
- The lectureship will be presented to an individual investigator.
- Institutions or organizations are not eligible for the lectureship.
Nominations are closed.
Nominations may be made by any scientist, whether an AACR member or nonmember, who is now or has been affiliated with any institution involved in cancer research, cancer medicine or cancer-related biomedical science. Candidates may not nominate themselves.
Nomination Procedure and Instructions
Nominations must be emailed to firstname.lastname@example.org by 4:00 p.m. United States Eastern Time on Thursday, October 3, 2013. Paper nominations will not be accepted.
Nomination Materials to be Submitted are:
1) Nomination Letter Must:
- be addressed to the Selection Committee; be written in English; and not exceed 1,000 words;
- specify the AACR Award for which the candidate is being nominated;
- describe the candidate's contributions to the field of cancer research, with the publications supporting these contributions directly referenced within the letter, and to the advancement of minority investigators in cancer research;
- contain a concise description of the impact of these accomplishments on the field; and
- be signed by the nominator(s).
2) Candidate's CV. The candidate's curriculum vitae in English, including a complete list of the candidate's publications.
3) Summary Statement. A statement, no more than 50 words, summarizing the candidate's research accomplishments for which he or she is being nominated.
Full nomination instructions and program guidelines are available at the following link:
Candidates will be considered by a Selection Committee of international cancer leaders appointed by the president of the AACR. After careful deliberations by the committee, its recommendations will be forwarded to the Executive Committee of the AACR for final consideration and decision. Selection of the winner will be made on the basis of the candidate's contributions to the field of cancer research and to the advancement of minorities. No regard will be given to age, race, gender, nationality, geographic location or religious or political views.
Supported by AACR-Minorities in Cancer Research.
Linda Stokes, Program Associate
American Association for Cancer Research
17th Floor, 615 Chestnut Street
Philadelphia, PA 19106-4404
Eighth Annual Award Recipient
Gabriel N. Hortobagyi, M.D.
Professor and Chair
Department of Breast Medical Oncology
UT MD Anderson Cancer Center
Dr. Hortobagyi delivered his award lecture titled Dual Targeting for Endocrine Therapy of Breast Cancer, at the AACR Annual Meeting 2013 in Washington, D.C. The award ceremony and lecture was held on Sunday, April 7, 2013. Visit the AACR Annual Meeting 2013 page for more information on the Annual Meeting.
Dr. Gabriel N. Hortobagyi is a Professor of Medicine, holding the Nellie B. Connally Chair in Breast Cancer within the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, where he remains as the Department Chair.
Dr. Hortobagyi has had a long and distinguished career that began with his undergraduate degree at Colegio Helvetia, Bogotá, Colombia prior to obtaining his medical degree at Universidad Nacional de Colombia, Bogotá, Colombia. He then continued his clinical training at St. Luke's Hospital, Case-Western Reserve University, Cleveland, Ohio and then Fellowships in Developmental Therapeutics and Medical Oncology at The University of Texas MD Anderson Hospital and Tumor Institute, Houston, Texas. Dr Hortobagyi has remained at The University of Texas MD Anderson Cancer Center rising through the ranks to become the founding departmental chair and the Nellie B. Connally Chair in Breast Cancer.
Dr. Hortobagyi is a past President of the American Society of Clinical Oncology (ASCO) and chairs the Breast Committee of the Southwest Oncology Group as well as the Operational Efficiency Working Group of the NCI. Dr Hortobagyi is an outstanding role model for clinical scientists and particularly so for minority scientists many of whom he has mentored and trained over the years. This combination of medical students, clinical residents and fellows numbers in excess of 100, many of whom have gone onto independent academic careers and leadership positions at other institutions around the world.
Dr. Hortobagyi's extensive research activities include combination chemotherapy regimens, presurgical chemotherapy, and targeted therapies for all stages of breast cancer. He has a truly impressive body of publications including more than 900 scientific journal articles, contributed over 130 chapters to textbooks and in addition he has authored and co-authored 13 books. He has served as Editor or Associate Editor for 17 scientific journals and was/is member of the editorial boards of 41 journals. For the past 3-5 years, his research has focused on the development and implementation of large multicenter hypothesis-driven clinical trials, largely focused on hormone receptor-positive breast cancer.
For his efforts in breast cancer research, Dr. Hortobagyi has received numerous worldwide honors including the Lederle Lecture, University of Nottingham, Nottingham, U.K. in 1992 and the Brinker International Award for Clinical Research from the Susan G. Komen Breast Cancer Foundation, 1997. In 2001, President Jacques Chirac named him Chevalier of the Order of la Legion d'Honneur de France. In 2003, Dr. Hortobagyi received the Glen Robbins Award in Breast Cancer Research from the New York Cancer Society and the Metropolitan Breast Cancer Group, and the Bristol-Myers Squibb 2003 Horizon Scientific Award. The Mexican Society of Oncology named him the 2005 World Leader in Oncology. In 2006 he received the Pathfinder Award from the American Society of Breast Diseases; in 2007, he received the Cruz Civica from the Colombian Government in 2009, he was elected to receive the ASCO Statesman Award, the Charles A. LeMaistre Outstanding Achievement Award and the John Mendelsohn Lifetime Scientific Achevement Award; in 2011, he was the recipient of the Dr. Jenaro Haddock Prize and Memorial lecture and the Bob Pinedo Cancer Care Award from the Society for Translational Oncology. In 2012, he received the Jill Rose Award from the Breast Cancer Research Foundation and the William L. McGuire Award at the CTRC-AACR San Antonio Breast Cancer Symposium. He is an elected member of 15 professional societies, honorary member of 17 others and received honorary doctorates from the universities of Modena (Italy), Nuevo Leon (Mexico) and Buenos Aires (Argentina). He is a member of the National Academy of Medicine and Sciences of Argentina, Hungary, and Mexico.